Gilead Sciences, Inc. (BIT:1GILD)

Market Cap	153.49B +35.7%
Revenue (ttm)	25.08B +2.4%
Net Income	7.25B +1,672.9%
EPS	5.77 +1,684.2%
Shares Out	n/a
PE Ratio	21.18
Forward PE	16.74
Dividend	2.76 (2.19%)
Ex-Dividend Date	Dec 12, 2025

Volume	275
Average Volume	193
Open	122.78
Previous Close	126.06
Day's Range	122.78 - 131.38
52-Week Range	82.79 - 131.38
Beta	0.39
RSI	74.10
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1GILD

Financial Performance

In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.

Financial numbers in USD